Neuromodulation Platform
Parkinson's Disease
About Subsense
Subsense is pioneering a novel, non-invasive brain-computer interface platform that uses functional nanoparticles as neural antennas and a wearable device for external control. Founded in 2019 and based in San Francisco, the company is targeting major neurological disorders as its initial medical application, with a longer-term vision for cognitive enhancement and human-AI integration. It has raised significant seed funding, opened a lab in Palo Alto, and initiated early regulatory engagement with the FDA, positioning itself as a disruptive player in the competitive neurotech landscape.
View full company profileAbout Subsense
Subsense is pioneering a novel, non-invasive brain-computer interface platform that uses functional nanoparticles as neural antennas and a wearable device for external control. Founded in 2019 and based in San Francisco, the company is targeting major neurological disorders as its initial medical application, with a longer-term vision for cognitive enhancement and human-AI integration. It has raised significant seed funding, opened a lab in Palo Alto, and initiated early regulatory engagement with the FDA, positioning itself as a disruptive player in the competitive neurotech landscape.
View full company profileTherapeutic Areas
Other Parkinson's Disease Drugs
| Drug | Company | Phase |
|---|---|---|
| NPT200-11 | Neuropore Therapies | Phase 1 |
| NUZ-001 | Neurizon Therapeutics | Preclinical |
| VXX-301 | Vaxxinity | Preclinical |
| BAN2802 | BioArctic | Phase 1 |
| CNM-Au8 | Clene | Phase 2 |
| hpSC-Derived Neural/Dopaminergic Cells | International Stem Cell | Preclinical/Early Clinical |
| SLS-004 | Seelos Therapeutics | Preclinical |
| SLS-007 | Seelos Therapeutics | Preclinical |
| Parkinson's Disease Portfolio (Platform-derived) | WD Pharmaceutical | Not Disclosed (Likely Preclinical/Early Clinical) |
| UX-DA001 | UniXell | Phase 1 |
| Parkinson's Disease Research | ProgenaBiome | Research |
| A9 Dopaminergic Neuron Therapy | Trailhead Biosystems | Pre-clinical |